{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T14:26:18Z","timestamp":1783779978595,"version":"3.55.0"},"reference-count":95,"publisher":"Japanese Society of Internal Medicine","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026]]},"DOI":"10.2169\/internalmedicine.7161-26","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T22:10:31Z","timestamp":1774303831000},"source":"Crossref","is-referenced-by-count":1,"title":["The Diagnosis and Management of Cardiac Sarcoidosis"],"prefix":"10.2169","author":[{"given":"Toshiyuki","family":"Nagai","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshifumi","family":"Tamura","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihisa","family":"Anzai","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Drent M, Crouser ED, Grunewald J. Challenges of Sarcoidosis and Its Management. N Engl J Med 385: 1018-1032, 2021.","DOI":"10.1056\/NEJMra2101555"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. De Bortoli A, Birnie DH. Diagnosis and Treatment of Cardiac Sarcoidosis. Circ J 87: 471-480, 2023.","DOI":"10.1253\/circj.CJ-22-0671"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3. Cheng RK, Kittleson MM, Beavers CJ, et al. Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association. Circulation 149: e1197-e1216, 2024.","DOI":"10.1161\/CIR.0000000000001240"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Malhi JK, Ibecheozor C, Chrispin J, et al. Diagnostic and management strategies in cardiac sarcoidosis. Int J Cardiol 403: 131853, 2024.","DOI":"10.1016\/j.ijcard.2024.131853"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Sharma R, Kouranos V, Cooper LT, et al. Management of cardiac sarcoidosis. Eur Heart J 45: 2697-2726, 2024.","DOI":"10.1093\/eurheartj\/ehae356"},{"key":"6","doi-asserted-by":"publisher","unstructured":"6. Belperio JA, Shaikh F, Abtin FG, et al. Diagnosis and Treatment of Pulmonary Sarcoidosis: A Review. JAMA 327: 856-867, 2022.","DOI":"10.1001\/jama.2022.1570"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Yazaki Y. How Should We Evaluate the Activity of Myocardial Inflammation and Guide Corticosteroid Treatment in Patients With Cardiac Sarcoidosis? Circ J 79: 1450-1452, 2015.","DOI":"10.1253\/circj.CJ-15-0583"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Nagai T, Inomata T, Kohno T, et al. JCS 2023 Guideline on the Diagnosis and Treatment of Myocarditis. Circ J 87: 674-754, 2023.","DOI":"10.1253\/circj.CJ-22-0696"},{"key":"9","unstructured":"9. Schulz-Menger J, Collini V, Gr\u00f6schel J, et al. 2025 ESC Guidelines for the management of myocarditis and pericarditis. Eur Heart J 2025."},{"key":"10","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.hrthm.2014.03.043","volume":"11","author":"DH Birnie","year":"2014","unstructured":"10. Birnie DH, Sauer WH, Bogun F, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm 11: 1305-1323, 2014.","journal-title":"Heart Rhythm","ISSN":"https:\/\/id.crossref.org\/issn\/1547-5271","issn-type":"print"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Terasaki F, Azuma A, Anzai T, et al. JCS 2016 Guideline on Diagnosis and Treatment of Cardiac Sarcoidosis - Digest Version. Circ J 83: 2329-2388, 2019.","DOI":"10.1253\/circj.CJ-19-0508"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Iwai K, Tachibana T, Takemura T, et al. Pathological studies on sarcoidosis autopsy. I. Epidemiological features of 320 cases in Japan. Acta Pathol Jpn 43: 372-376, 1993.","DOI":"10.1111\/j.1440-1827.1993.tb01148.x"},{"key":"13","doi-asserted-by":"publisher","unstructured":"13. Silverman KJ, Hutchins GM, Bulkley BH. Cardiac sarcoid: a clinicopathologic study of 84 unselected patients with systemic sarcoidosis. Circulation 58: 1204-1211, 1978.","DOI":"10.1161\/01.CIR.58.6.1204"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. P\u00f6yh\u00f6nen P, Lehtonen J, Velikanova D, et al. 30-Year Trends in the Incidence, Characteristics, and Outcome of Cardiac Sarcoidosis in a Nationwide Cohort. JACC Adv 3: 101102, 2024.","DOI":"10.1016\/j.jacadv.2024.101102"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Obi ON, Sharp M, Harper L. Progress for all: addressing disparities in sarcoidosis. Curr Opin Pulm Med 30: 551-560, 2024.","DOI":"10.1097\/MCP.0000000000001104"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Casipit BA, Lo KB, Casipit CG, et al. Impact of comorbid heart failure among hospitalized patients with sarcoidosis: A United States population-based cohort study. Int J Cardiol Heart Vasc 49: 101275, 2023.","DOI":"10.1016\/j.ijcha.2023.101275"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Harper LJ, Tauquir A, Huang S, et al. Comparison of organ involvement clusters in Black and White American sarcoidosis patients from a prospectively collected patient registry. Respir Med 226: 107605, 2024.","DOI":"10.1016\/j.rmed.2024.107605"},{"key":"18","doi-asserted-by":"publisher","unstructured":"18. Kusano K, Ishibashi K, Noda T, et al. Prognosis and Outcomes of Clinically Diagnosed Cardiac Sarcoidosis Without Positive Endomyocardial Biopsy Findings. JACC Asia 1: 385-395, 2021.","DOI":"10.1016\/j.jacasi.2021.09.005"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Roberts WC, McAllister HA Jr., Ferrans VJ. Sarcoidosis of the heart. A clinicopathologic study of 35 necropsy patients (group 1) and review of 78 previously described necropsy patients (group 11). Am J Med 63: 86-108, 1977.","DOI":"10.1016\/0002-9343(77)90145-0"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Mathai SV, Patel S, Jorde UP, et al. Epidemiology, Pathogenesis, and Diagnosis of Cardiac Sarcoidosis. Methodist Debakey Cardiovasc J 18: 78-93, 2022.","DOI":"10.14797\/mdcvj.1057"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med 357: 2153-2165, 2007.","DOI":"10.1056\/NEJMra071714"},{"key":"22","unstructured":"22. Uemura A, Morimoto S, Kato Y, et al. Relationship between basal thinning of the interventricular septum and atrioventricular block in patients with cardiac sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 22: 63-65, 2005."},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Miyazawa K, Yoshikawa T, Takamisawa I, et al. Presence of ventricular aneurysm predicts poor clinical outcomes in patients with cardiac sarcoidosis. Int J Cardiol 177: 720-722, 2014.","DOI":"10.1016\/j.ijcard.2014.10.024"},{"key":"24","unstructured":"24. Muser D, Santangeli P, Liang JJ, et al. Characterization of the Electroanatomic Substrate in Cardiac Sarcoidosis: Correlation With Imaging Findings of Scar and Inflammation. JACC Clin Electrophysiol 4: 291-303, 2018."},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Riezzo I, Ventura F, D'Errico S, et al. Arrhythmogenesis and diagnosis of cardiac sarcoidosis. An immunohistochemical study in a sudden cardiac death. Forensic Sci Int 183: e1-e5, 2009.","DOI":"10.1016\/j.forsciint.2008.09.020"},{"key":"26","doi-asserted-by":"publisher","unstructured":"26. Banba K, Kusano KF, Nakamura K, et al. Relationship between arrhythmogenesis and disease activity in cardiac sarcoidosis. Heart Rhythm 4: 1292-1299, 2007.","DOI":"10.1016\/j.hrthm.2007.06.006"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Kazui S, Takenaka S, Nagai T, et al. Prognostic Value of Combined Assessments of Late Gadolinium Enhancement and Fluorodeoxyglucose Uptake in Cardiac Sarcoidosis. JACC Cardiovasc Imaging 17: 710-712, 2024.","DOI":"10.1016\/j.jcmg.2024.01.010"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Birnie DH, Nery PB, Ha AC, et al. Cardiac Sarcoidosis. J Am Coll Cardiol 68: 411-421, 2016.","DOI":"10.1016\/j.jacc.2016.03.605"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Miedema J, Cinetto F, Smed-S\u00f6rensen A, et al. The immunopathogenesis of sarcoidosis. J Autoimmun 149: 103247, 2024.","DOI":"10.1016\/j.jaut.2024.103247"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Ueberham L, Hagendorff A, Klingel K, et al. Pathophysiological Gaps, Diagnostic Challenges, and Uncertainties in Cardiac Sarcoidosis. J Am Heart Assoc 12: e027971, 2023.","DOI":"10.1161\/JAHA.122.027971"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Kato S, Sakai Y, Okabe A, et al. Histology of Cardiac Sarcoidosis with Novel Considerations Arranged upon a Pathologic Basis. J Clin Med 11: 2022.","DOI":"10.3390\/jcm11010251"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Nordenswan HK, Lehtonen J, Ekstr\u00f6m K, et al. Manifestations and Outcome of Cardiac Sarcoidosis and Idiopathic Giant Cell Myocarditis by 25-Year Nationwide Cohorts. J Am Heart Assoc 10: e019415, 2021.","DOI":"10.1161\/JAHA.120.019415"},{"key":"33","doi-asserted-by":"publisher","unstructured":"33. Mehta D, Lubitz SA, Frankel Z, et al. Cardiac involvement in patients with sarcoidosis: diagnostic and prognostic value of outpatient testing. Chest 133: 1426-1435, 2008.","DOI":"10.1378\/chest.07-2784"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Kim SJ, Pak K, Kim K. Diagnostic performance of F-18 FDG PET for detection of cardiac sarcoidosis; A systematic review and meta-analysis. J Nucl Cardiol 27: 2103-2115, 2020.","DOI":"10.1007\/s12350-018-01582-y"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Kouranos V, Tzelepis GE, Rapti A, et al. Complementary Role of CMR to Conventional Screening in the Diagnosis and Prognosis of Cardiac Sarcoidosis. JACC Cardiovasc Imaging 10: 1437-1447, 2017.","DOI":"10.1016\/j.jcmg.2016.11.019"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Momose M, Kadoya M, Koshikawa M, et al. Usefulness of 67Ga SPECT and integrated low-dose CT scanning (SPECT\/CT) in the diagnosis of cardiac sarcoidosis. Ann Nucl Med 21: 545-551, 2007.","DOI":"10.1007\/s12149-007-0064-5"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Uemura A, Morimoto S, Hiramitsu S, et al. Histologic diagnostic rate of cardiac sarcoidosis: evaluation of endomyocardial biopsies. Am Heart J 138: 299-302, 1999.","DOI":"10.1016\/S0002-8703(99)70115-8"},{"key":"38","doi-asserted-by":"publisher","unstructured":"38. Kandolin R, Lehtonen J, Airaksinen J, et al. Cardiac sarcoidosis: epidemiology, characteristics, and outcome over 25 years in a nationwide study. Circulation 131: 624-632, 2015.","DOI":"10.1161\/CIRCULATIONAHA.114.011522"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Ohira H, Sato T, Manabe O, et al. Underdiagnosis of cardiac sarcoidosis by ECG and echocardiography in cases of extracardiac sarcoidosis. ERJ Open Res 8: 2022.","DOI":"10.1183\/23120541.00516-2021"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Kawai H, Naruse H, Sarai M, et al. Serum angiotensin-converting enzyme levels indicating early sarcoidosis diagnosis and immunosuppressive therapy efficacy. ESC Heart Fail 10: 1803-1810, 2023.","DOI":"10.1002\/ehf2.14343"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Kandolin R, Lehtonen J, Airaksinen J, et al. Usefulness of Cardiac Troponins as Markers of Early Treatment Response in Cardiac Sarcoidosis. Am J Cardiol 116: 960-964, 2015.","DOI":"10.1016\/j.amjcard.2015.06.021"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Kazui S, Takenaka S, Nagai T, et al. Association of longitudinal cardiac troponin trajectory with adverse events in patients with cardiac sarcoidosis. Int J Cardiol 389: 131268, 2023.","DOI":"10.1016\/j.ijcard.2023.131268"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Kobayashi Y, Sato T, Nagai T, et al. Association of high serum soluble interleukin 2 receptor levels with risk of adverse events in cardiac sarcoidosis. ESC Heart Fail 8: 5282-5292, 2021.","DOI":"10.1002\/ehf2.13614"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Joyce E, Kamperidis V, Ninaber MK, et al. Prevalence and Correlates of Early Right Ventricular Dysfunction in Sarcoidosis and Its Association with Outcome. J Am Soc Echocardiogr 29: 871-878, 2016.","DOI":"10.1016\/j.echo.2016.06.001"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Joyce E, Ninaber MK, Katsanos S, et al. Subclinical left ventricular dysfunction by echocardiographic speckle-tracking strain analysis relates to outcome in sarcoidosis. Eur J Heart Fail 17: 51-62, 2015.","DOI":"10.1002\/ejhf.205"},{"key":"46","doi-asserted-by":"publisher","unstructured":"46. Ise T, Hasegawa T, Morita Y, et al. Extensive late gadolinium enhancement on cardiovascular magnetic resonance predicts adverse outcomes and lack of improvement in LV function after steroid therapy in cardiac sarcoidosis. Heart 100: 1165-1172, 2014.","DOI":"10.1136\/heartjnl-2013-305187"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. P\u00f6yh\u00f6nen P, Lehtonen J, Syv\u00e4ranta S, et al. Magnetic Resonance Imaging in the Assessment of the Risk of Sudden Death in Cardiac Sarcoidosis: What Is Extensive or Significant Late Gadolinium Enhancement? Circ Arrhythm Electrophysiol 18: e013239, 2025.","DOI":"10.1161\/CIRCEP.124.013239"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Nadel J, Lancefield T, Voskoboinik A, et al. Late gadolinium enhancement identified with cardiac magnetic resonance imaging in sarcoidosis patients is associated with long-term ventricular arrhythmia and sudden cardiac death. Eur Heart J Cardiovasc Imaging 16: 634-641, 2015.","DOI":"10.1093\/ehjci\/jeu294"},{"key":"49","doi-asserted-by":"publisher","unstructured":"49. Nagai T, Kohsaka S, Okuda S, et al. Incidence and prognostic significance of myocardial late gadolinium enhancement in patients with sarcoidosis without cardiac manifestation. Chest 146: 1064-1072, 2014.","DOI":"10.1378\/chest.14-0139"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50. Ekstr\u00f6m K, Lehtonen J, H\u00e4nninen H, et al. Magnetic Resonance Imaging as a Predictor of Survival Free of Life-Threatening Arrhythmias and Transplantation in Cardiac Sarcoidosis. J Am Heart Assoc 5: 2016.","DOI":"10.1161\/JAHA.115.003040"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51. Murtagh G, Laffin LJ, Beshai JF, et al. Prognosis of Myocardial Damage in Sarcoidosis Patients With Preserved Left Ventricular Ejection Fraction: Risk Stratification Using Cardiovascular Magnetic Resonance. Circ Cardiovasc Imaging 9: e003738, 2016.","DOI":"10.1161\/CIRCIMAGING.115.003738"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52. Coleman GC, Shaw PW, Balfour PC Jr., et al. Prognostic Value of Myocardial Scarring on CMR in Patients With Cardiac Sarcoidosis. JACC Cardiovasc Imaging 10: 411-420, 2017.","DOI":"10.1016\/j.jcmg.2016.05.009"},{"key":"53","doi-asserted-by":"publisher","unstructured":"53. Puntmann VO, Isted A, Hinojar R, et al. T1 and T2 Mapping in Recognition of Early Cardiac Involvement in Systemic Sarcoidosis. Radiology 285: 63-72, 2017.","DOI":"10.1148\/radiol.2017162732"},{"key":"54","doi-asserted-by":"publisher","unstructured":"54. Crouser ED, Ruden E, Julian MW, et al. Resolution of Abnormal Cardiac Mri T2 Signal following Immune Suppression for Cardiac Sarcoidosis. Journal of Investigative Medicine 64: 1148-1150, 2016.","DOI":"10.1136\/jim-2016-000144"},{"key":"55","doi-asserted-by":"publisher","unstructured":"55. Kumita S, Yoshinaga K, Miyagawa M, et al. Recommendations for 18F-fluorodeoxyglucose positron emission tomography imaging for diagnosis of cardiac sarcoidosis-2018 update: Japanese Society of Nuclear Cardiology recommendations. Journal of Nuclear Cardiology 26: 1414-1433, 2019.","DOI":"10.1007\/s12350-019-01755-3"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56. Kato T, Niizuma S, Inuzuka Y, et al. Analysis of metabolic remodeling in compensated left ventricular hypertrophy and heart failure. Circ Heart Fail 3: 420-430, 2010.","DOI":"10.1161\/CIRCHEARTFAILURE.109.888479"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57. Tamura T, Tsuneta S, Nagai T. Cardiac sarcoidosis with multiple intracardiac masses diagnosed by rectus femoris biopsy. Eur Heart J 46: 667, 2025.","DOI":"10.1093\/eurheartj\/ehae840"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58. Trivieri MG, Robson PM, Vergani V, et al. Hybrid Magnetic Resonance Positron Emission Tomography Is Associated With Cardiac-Related Outcomes in Cardiac Sarcoidosis. JACC Cardiovasc Imaging 17: 411-424, 2024.","DOI":"10.1016\/j.jcmg.2023.11.010"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59. Ardehali H, Howard DL, Hariri A, et al. A positive endomyocardial biopsy result for sarcoid is associated with poor prognosis in patients with initially unexplained cardiomyopathy. Am Heart J 150: 459-463, 2005.","DOI":"10.1016\/j.ahj.2004.10.006"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60. Lehtonen J, Uusitalo V, P\u00f6yh\u00f6nen P, et al. Cardiac sarcoidosis: phenotypes, diagnosis, treatment, and prognosis. Eur Heart J 44: 1495-1510, 2023.","DOI":"10.1093\/eurheartj\/ehad067"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61. Hiramitsu S, Hiroe M, Uemura A, et al. National survey of the use of endomyocardial biopsy in Japan. Jpn Circ J 62: 909-912, 1998.","DOI":"10.1253\/jcj.62.909"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62. Kitai T, Kohsaka S, Kato T, et al. JCS\/JHFS 2025 Guideline on Diagnosis and Treatment of Heart Failure. Circ J 89: 1278-1444, 2025.","DOI":"10.1253\/circj.CJ-25-0002"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63. Komoriyama H, Omote K, Nagai T, et al. Lower left ventricular ejection fraction and higher serum angiotensin-converting enzyme activity are associated with histopathological diagnosis by endomyocardial biopsy in patients with cardiac sarcoidosis. Int J Cardiol 321: 113-117, 2020.","DOI":"10.1016\/j.ijcard.2020.07.034"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64. Honda Y, Nagai T, Ikeda Y, et al. Myocardial Immunocompetent Cells and Macrophage Phenotypes as Histopathological Surrogates for Diagnosis of Cardiac Sarcoidosis in Japanese. J Am Heart Assoc 5: 2016.","DOI":"10.1161\/JAHA.116.004019"},{"key":"65","unstructured":"65. Judson MA, Costabel U, Drent M, et al. The WASOG Sarcoidosis Organ Assessment Instrument: An update of a previous clinical tool. Sarcoidosis Vasc Diffuse Lung Dis 31: 19-27, 2014."},{"key":"66","doi-asserted-by":"crossref","unstructured":"66. Tanaka TD, Nagai T, Nagoshi T, et al. Diagnosis of cardiac sarcoidosis despite negative findings on serial late gadolinium enhancement with cardiac magnetic resonance imaging\/(18)F-fluorodeoxyglucose positron emission tomography examinations. J Nucl Cardiol 27: 2149-2153, 2020.","DOI":"10.1007\/s12350-019-01968-6"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67. Takeuchi T, Yazaki Y, Okada A, et al. Failure of steroid withdrawal guided by (18)F-FDG PET in a patient with cardiac sarcoidosis. J Cardiol Cases 15: 10-13, 2017.","DOI":"10.1016\/j.jccase.2016.09.006"},{"key":"68","doi-asserted-by":"crossref","unstructured":"68. Nagai T, Nagano N, Sugano Y, et al. Effect of Discontinuation of Prednisolone Therapy on Risk of Cardiac Mortality Associated With Worsening Left Ventricular Dysfunction in Cardiac Sarcoidosis. Am J Cardiol 117: 966-971, 2016.","DOI":"10.1016\/j.amjcard.2015.12.033"},{"key":"69","doi-asserted-by":"crossref","unstructured":"69. Morimoto R, Unno K, Fujita N, et al. Prospective Analysis of Immunosuppressive Therapy in Cardiac Sarcoidosis With Fluorodeoxyglucose Myocardial Accumulation: The PRESTIGE Study. JACC Cardiovasc Imaging 17: 45-58, 2024.","DOI":"10.1016\/j.jcmg.2023.05.017"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70. Birnie D, Beanlands RSB, Nery P, et al. Cardiac Sarcoidosis multi-center randomized controlled trial (CHASM CS- RCT). Am Heart J 220: 246-252, 2020.","DOI":"10.1016\/j.ahj.2019.10.003"},{"key":"71","doi-asserted-by":"crossref","unstructured":"71. Kron J, Crawford T, Bogun F, et al. Interleukin-1 Blockade in Cardiac Sarcoidosis: A Pilot Study. Circ Arrhythm Electrophysiol 16: e011869, 2023.","DOI":"10.1161\/CIRCEP.123.011869"},{"key":"72","doi-asserted-by":"crossref","unstructured":"72. Kaneta K, Takahama H, Tateishi E, et al. Clinical Outcomes of Radiologic Relapse in Patients With Cardiac Sarcoidosis Under Immunosuppressive Therapies. Am J Cardiol 188: 24-29, 2023.","DOI":"10.1016\/j.amjcard.2022.10.048"},{"key":"73","doi-asserted-by":"crossref","unstructured":"73. Shabtaie SA, Sehrawat O, Lee JZ, et al. Cardiac resynchronization therapy response in cardiac sarcoidosis. J Cardiovasc Electrophysiol 33: 2072-2080, 2022.","DOI":"10.1111\/jce.15631"},{"key":"74","doi-asserted-by":"crossref","unstructured":"74. Chicos AB. Does cardiac resynchronization help patients with cardiac sarcoidosis? J Cardiovasc Electrophysiol 33: 2081-2082, 2022.","DOI":"10.1111\/jce.15633"},{"key":"75","doi-asserted-by":"crossref","unstructured":"75. Bobbio E, Bj\u00f6rkenstam M, Nwaru BI, et al. Short- and long-term outcomes after heart transplantation in cardiac sarcoidosis and giant-cell myocarditis: a systematic review and meta-analysis. Clinical Research in Cardiology 111: 125-140, 2022.","DOI":"10.1007\/s00392-021-01920-0"},{"key":"76","doi-asserted-by":"publisher","unstructured":"76. Asleh R, Briasoulis A, Doulamis I, et al. Outcomes after heart transplantation in patients with cardiac sarcoidosis. ESC Heart Failure 9: 1167-1174, 2022.","DOI":"10.1002\/ehf2.13789"},{"key":"77","doi-asserted-by":"publisher","unstructured":"77. Jackson KC, Youmans QR, Wu T, et al. Heart transplantation outcomes in cardiac sarcoidosis. The Journal of Heart and Lung Transplantation 41: 113-122, 2022.","DOI":"10.1016\/j.healun.2021.08.012"},{"key":"78","doi-asserted-by":"publisher","unstructured":"78. Adhaduk M, Paudel B, Liu K, et al. Meta-Analysis of Catheter Ablation Outcomes in Patients With Cardiac Sarcoidosis Refractory Ventricular Tachycardia. The American Journal of Cardiology 174: 136-142, 2022.","DOI":"10.1016\/j.amjcard.2022.03.038"},{"key":"79","doi-asserted-by":"publisher","unstructured":"79. Siontis KC, Santangeli P, Muser D, et al. Outcomes Associated With Catheter Ablation of Ventricular Tachycardia in Patients With Cardiac Sarcoidosis. JAMA Cardiology 7: 175-183, 2022.","DOI":"10.1001\/jamacardio.2021.4738"},{"key":"80","doi-asserted-by":"crossref","unstructured":"80. Ekstr\u00f6m K, Lehtonen J, Nordenswan HK, et al. Sudden death in cardiac sarcoidosis: an analysis of nationwide clinical and cause-of-death registries. Eur Heart J 40: 3121-3128, 2019.","DOI":"10.1093\/eurheartj\/ehz428"},{"key":"81","doi-asserted-by":"crossref","unstructured":"81. Nabeta T, Kitai T, Naruse Y, et al. Risk stratification of patients with cardiac sarcoidosis: the ILLUMINATE-CS registry. Eur Heart J 43: 3450-3459, 2022.","DOI":"10.1093\/eurheartj\/ehac323"},{"key":"82","doi-asserted-by":"crossref","unstructured":"82. Takaya Y, Kusano K, Nishii N, et al. Early and frequent defibrillator discharge in patients with cardiac sarcoidosis compared with patients with idiopathic dilated cardiomyopathy. Int J Cardiol 240: 302-306, 2017.","DOI":"10.1016\/j.ijcard.2017.04.044"},{"key":"83","doi-asserted-by":"crossref","unstructured":"83. Nordenswan HK, Lehtonen J, Ekstr\u00f6m K, et al. Outcome of Cardiac Sarcoidosis Presenting With High-Grade Atrioventricular Block. Circ Arrhythm Electrophysiol 11: e006145, 2018.","DOI":"10.1161\/CIRCEP.117.006145"},{"key":"84","doi-asserted-by":"crossref","unstructured":"84. O'Mahony C, Jichi F, Pavlou M, et al. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). Eur Heart J 35: 2010-2020, 2014.","DOI":"10.1093\/eurheartj\/eht439"},{"key":"85","doi-asserted-by":"crossref","unstructured":"85. Takaya Y, Kusano KF, Nakamura K, et al. Outcomes in patients with high-degree atrioventricular block as the initial manifestation of cardiac sarcoidosis. Am J Cardiol 115: 505-509, 2015.","DOI":"10.1016\/j.amjcard.2014.11.028"},{"key":"86","doi-asserted-by":"publisher","unstructured":"86. Kamada H, Ishibashi K, Miyazaki Y, et al. Fatal Arrhythmic Risks in Cardiac Sarcoidosis With Mildly Impaired Cardiac Function. JACC Asia 3: 755-763, 2023.","DOI":"10.1016\/j.jacasi.2023.07.006"},{"key":"87","doi-asserted-by":"crossref","unstructured":"87. Curtis AB, Worley SJ, Adamson PB, et al. Biventricular pacing for atrioventricular block and systolic dysfunction. N Engl J Med 368: 1585-1593, 2013.","DOI":"10.1056\/NEJMoa1210356"},{"key":"88","doi-asserted-by":"crossref","unstructured":"88. Ueda A, Nakagawa K, Miyamoto K, et al. Early Corticosteroid Therapy and Its Effect on Ventricular Tachyarrhythmia Recurrence in Cardiac Sarcoidosis: A 10-Year Longitudinal Multicenter Study. J Cardiovasc Electrophysiol 36: 1386-1394, 2025.","DOI":"10.1111\/jce.16685"},{"key":"89","doi-asserted-by":"crossref","unstructured":"89. Segawa M, Fukuda K, Nakano M, et al. Time Course and Factors Correlating With Ventricular Tachyarrhythmias After Introduction of Steroid Therapy in Cardiac Sarcoidosis. Circ Arrhythm Electrophysiol 9: 2016.","DOI":"10.1161\/CIRCEP.115.003353"},{"key":"90","doi-asserted-by":"crossref","unstructured":"90. Zeppenfeld K, Tfelt-Hansen J, de Riva M, et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J 43: 3997-4126, 2022.","DOI":"10.1093\/eurheartj\/ehac699"},{"key":"91","doi-asserted-by":"crossref","unstructured":"91. Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA\/ACC\/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation 138: e272-e391, 2018.","DOI":"10.1161\/CIR.0000000000000614"},{"key":"92","doi-asserted-by":"publisher","unstructured":"92. Kusano KF, Satomi K. Diagnosis and treatment of cardiac sarcoidosis. Heart 102: 184-190, 2016.","DOI":"10.1136\/heartjnl-2015-307877"},{"key":"93","doi-asserted-by":"crossref","unstructured":"93. Muser D, Santangeli P, Pathak RK, et al. Long-Term Outcomes of Catheter Ablation of Ventricular Tachycardia in Patients With Cardiac Sarcoidosis. Circ Arrhythm Electrophysiol 9: 2016.","DOI":"10.1161\/CIRCEP.116.004333"},{"key":"94","doi-asserted-by":"crossref","unstructured":"94. Takenaka S, Kobayashi Y, Nagai T, et al. Applicability of the AHA\/ACC\/HRS Guideline for Implantable Cardioverter Defibrillator Implantation in Japanese Patients With Cardiac Sarcoidosis. JACC Clin Electrophysiol 7: 1410-1418, 2021.","DOI":"10.1016\/j.jacep.2021.04.009"},{"key":"95","doi-asserted-by":"crossref","unstructured":"95. Mathijssen H, Bawaskar PH, Rochlani Y, et al. Prediction of ventricular arrhythmic outcomes in suspected cardiac sarcoidosis: a comparison of cardiovascular magnetic resonance phenotyping vs. societal recommendations for implantable cardioverter-defibrillator placement. Eur Heart J 46: 3583-3596, 2025.","DOI":"10.1093\/eurheartj\/ehaf338"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_7161-26\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T03:25:02Z","timestamp":1774668302000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_7161-26\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":95,"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.7161-26","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"7161-26"}}